Welcome
Support Centre
12 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
Trial of Homocysteine Reduction In the prevention of Vascular Events and Dementia in the elderly
ISRCTN ISRCTN07337345
ClinicalTrials.gov identifier
Public title Trial of Homocysteine Reduction In the prevention of Vascular Events and Dementia in the elderly
Scientific title
Acronym THRIVED
Serial number at source 112/57
Study hypothesis 1. What are the effects of vitamin combinations (comprising of folic acid plus B12, B6 and B2, each alone and in combination) on serum homocysteine (HCY) in elderly patients with vascular disease?
2. Is telephone follow-up of cognitive function and of disability practicable in this cohort of patients?
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Ischaemic vascular disease
Participants - inclusion criteria 1. Age greater than 65 years
2. Ischaemic vascular disease (at least one of the following: history of angina pectoris, acute myocardial infarction, evidence of major ischaemia or previous infarction on 12-lead electrocardiogram, ischaemic stroke, transient ischaemic attack, intermittent claudication, previous surgery for ischaemic vascular disease)
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/12/2001
Anticipated end date 30/11/2003
Status of trial Completed
Patient information material
Target number of participants 100 elderly patients from Glasgow Royal Infirmary
Interventions Patients will receive vitamin folic acid (2 mg) plus vitamin B12 (400 mg) or placebo, vitamin B6 (25 mg) or placebo, and B2 (25 mg), in a factorial 2 by 2 design.
Primary outcome measure(s) 1. Serum HCY, plasma von Willebrand factor, vitamin levels (red cell folate, serum vitamin B12, B2 and B6)
2. Piloting of telephone follow-up of cognition (Telephone Interview for Cognitive Status [TICSm]) and of disability (Barthel Index and short Instrumental Activities for Daily Living [ADL] scale)
Secondary outcome measure(s) Not provided at time of registration
Sources of funding The Health Foundation (UK)
Trial website
Publications 2005 results in http://www.ncbi.nlm.nih.gov/pubmed/16332666
Contact name Dr  David J  Stott
  Address Academic Section of Geriatric Medicine
3rd Floor Centre Block
Glasgow Royal Infirmary
  City/town Glasgow
  Zip/Postcode G4 0SF
  Country United Kingdom
  Tel +44 (0)141 211 4976
  Fax +44-(0)141 211 4944
  Email d.j.stott@clinmed.gla.ac.uk
Sponsor The Health Foundation (UK)
  Address 90 Long Acre
  City/town London
  Zip/Postcode WC2E 9RA
  Country United Kingdom
  Tel +44 (0)20 7257 8000
  Fax +44 (0)20 7257 8001
  Email info@health.org.uk
  Sponsor website: http://www.pppfoundation.org.uk/
Date applied 12/09/2002
Last edited 05/01/2011
Date ISRCTN assigned 12/09/2002
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central